Identification of Epidermal Growth Factor Receptor Tyrosine-Kinase Mutations in Non-small Cell Lung Cancer: Testing Platform Matters

Personalized medicine using targeted therapies has revolutionized the management of non-small cell lung cancer (NSCLC) in the past decade. The discovery that sensitizing epidermal growth factor receptor (EGFR) mutations are predictive for therapeutic benefit from EGFR tyrosine kinase inhibitors (TKI...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandhi, Shipra, Kapoor, Ankita, Dy, Grace
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164712/
https://www.ncbi.nlm.nih.gov/pubmed/32313757
http://dx.doi.org/10.7759/cureus.7316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164712/
https://www.ncbi.nlm.nih.gov/pubmed/32313757
http://dx.doi.org/10.7759/cureus.7316

Ejemplares similares